Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process

Csaba Mártha, Levente Kürti, Gabriella Farkas, Orsolya Jójárt-Laczkovich, Balázs Szalontai, Erik Glässer, Mária A. Deli, Piroska Szabó-Révész

Research output: Contribution to journalArticle

16 Citations (Scopus)


Particle size reduction to the submicron region in a grinding process demands a high energy input. This grinding energy requirement can be reduced by means of a suitable additive, e.g. polymer, and performing a co-grinding process. Although these excipients promote attainment of the nanoparticle size range, they can also decrease the crystallinity of the active pharmaceutical ingredient. Different types of polymers have different abilities to amorphize the active material. To demonstrate the amorphization effects of different polymers, meloxicam (MX) as a model drug was subjected to co-grinding in the presence of one or other of four different polymers (PEG 6000, PEG 20,000, PVP C30 and PVP K25) and the products were investigated by XRPD, FT-IR and SEM. Although the PEG materials slightly melted and covered the MX particles during the grinding, they did not cause any changes in crystallinity. The PVP polymers softened and covered the MX particles, but drastically reduced the crystallinity of the drug. FT-IR revealed a weak secondary bonding between MX and the PVP polymer chain.

Original languageEnglish
Pages (from-to)2426-2432
Number of pages7
JournalEuropean Polymer Journal
Issue number9
Publication statusPublished - Sep 1 2013



  • Co-grinding
  • Crystallinity
  • Meloxicam
  • Polyethylene glycol
  • Polyvinylpyrrolidone

ASJC Scopus subject areas

  • Physics and Astronomy(all)
  • Organic Chemistry
  • Polymers and Plastics
  • Materials Chemistry

Cite this